MedTrace Logo

Aetiology of TemporaL Arteritis Study

NCT02584517 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-08-15

No results posted yet for this study

Summary

Giant Cell Arteritis (GCA) is the most common vasculitis and has significant morbidity in terms of blindness, stroke, and tissue necrosis. It requires protracted treatment with high-dose steroids, and despite this there is a risk of flare during the treatment. Little is known about the initial triggers for the inflammatory process, and there are no good markers of response or relapse. We will study patients referred with suspected GCA to identify important components of the immune response in GCA, and follow them over time to collect evidence of how best to monitor their condition.

Conditions

  • Temporal Arteritis

Sponsors & Collaborators

  • University of Leeds

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Raashid A Luqmani, DM FRCP · University of Oxford

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-01-31
Completion
2021-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02584517 on ClinicalTrials.gov